Literature DB >> 28776750

Generation of a non-transmissive Borna disease virus vector lacking both matrix and glycoprotein genes.

Kan Fujino1, Yusuke Yamamoto1,2, Takuji Daito1, Akiko Makino1, Tomoyuki Honda1, Keizo Tomonaga1,2,3.   

Abstract

Borna disease virus (BoDV), a prototype of mammalian bornavirus, is a non-segmented, negative strand RNA virus that often causes severe neurological disorders in infected animals, including horses and sheep. Unique among animal RNA viruses, BoDV transcribes and replicates non-cytopathically in the cell nucleus, leading to establishment of long-lasting persistent infection. This striking feature of BoDV indicates its potential as an RNA virus vector system. It has previously been demonstrated by our team that recombinant BoDV (rBoDV) lacking an envelope glycoprotein (G) gene develops persistent infections in transduced cells without loss of the viral genome. In this study, a novel non-transmissive rBoDV, rBoDV ΔMG, which lacks both matrix (M) and G genes in the genome, is reported. rBoDV-ΔMG expressing green fluorescence protein (GFP), rBoDV ΔMG-GFP, was efficiently generated in Vero/MG cells stably expressing both BoDV M and G proteins. Infection with rBoDV ΔMG-GFP was persistently maintained in the parent Vero cells without propagation within cell culture. The optimal ratio of M and G for efficient viral particle production by transient transfection of M and G expression plasmids into cells persistently infected with rBoDV ΔMG-GFP was also demonstrated. These findings indicate that the rBoDV ΔMG-based BoDV vector may provide an extremely safe virus vector system and could be a novel strategy for investigating the function of M and G proteins and the host range of bornaviruses.
© 2017 The Societies and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Borna disease virus; animal RNA virus; viral vector

Mesh:

Substances:

Year:  2017        PMID: 28776750     DOI: 10.1111/1348-0421.12505

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  7 in total

1.  Optimal Expression of the Envelope Glycoprotein of Orthobornaviruses Determines the Production of Mature Virus Particles.

Authors:  Madoka Sakai; Yoko Fujita; Ryo Komorizono; Takehiro Kanda; Yumiko Komatsu; Takeshi Noda; Keizo Tomonaga; Akiko Makino
Journal:  J Virol       Date:  2020-12-02       Impact factor: 5.103

2.  ADAR2 Is Involved in Self and Nonself Recognition of Borna Disease Virus Genomic RNA in the Nucleus.

Authors:  Mako Yanai; Shohei Kojima; Madoka Sakai; Ryo Komorizono; Keizo Tomonaga; Akiko Makino
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

3.  Splicing-Dependent Subcellular Targeting of Borna Disease Virus Nucleoprotein Isoforms.

Authors:  Shohei Kojima; Ryo Sato; Mako Yanai; Yumiko Komatsu; Masayuki Horie; Manabu Igarashi; Keizo Tomonaga
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

4.  The Borna Disease Virus 2 (BoDV-2) Nucleoprotein Is a Conspecific Protein That Enhances BoDV-1 RNA-Dependent RNA Polymerase Activity.

Authors:  Takehiro Kanda; Masayuki Horie; Yumiko Komatsu; Keizo Tomonaga
Journal:  J Virol       Date:  2021-08-18       Impact factor: 5.103

5.  Modeling Borna Disease Virus In Vitro Spread Reveals the Mode of Antiviral Effect Conferred by an Endogenous Bornavirus-Like Element.

Authors:  Kwang Su Kim; Yusuke Yamamoto; Shinji Nakaoka; Keizo Tomonaga; Shingo Iwami; Tomoyuki Honda
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

6.  Evolutionary Selection of the Nuclear Localization Signal in the Viral Nucleoprotein Leads to Host Adaptation of the Genus Orthobornavirus.

Authors:  Ryo Komorizono; Yukiko Sassa; Masayuki Horie; Akiko Makino; Keizo Tomonaga
Journal:  Viruses       Date:  2020-11-11       Impact factor: 5.048

7.  Development of an RNA Virus-Based Episomal Vector Capable of Switching Transgene Expression.

Authors:  Yusuke Yamamoto; Keizo Tomonaga; Tomoyuki Honda
Journal:  Front Microbiol       Date:  2019-11-06       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.